- Created on the 13 July, 2017.
Chikungunya is a member of the Togaviridae family of the alphavirus genus, it can be described as a mosquito-borne viral disease. Some of the many symptoms of this disease include muscle pain, severe joint pain, headache, rash, fever and fatigue. Chikungunya is found all around the world and it shares a number of clinical signs which are similar to dengue and zika virus. The virus is transmitted by a bite from an infected female mosquitoes from one human to another. ELISA assays are one of the most used serological tests which are routinely utilised in order to diagnose Chikungunya virus. Usually either IgM or IgG anti-chikungunya antibodies are used and in the case for IgM, it has been discovered that they are at their highest levels around the 3-5 week period after the onset of the infection and this usually persists for another 2 months.
Human Chikungunya virus-IgM ELISA kit is intended for measuring in-vitro quantitative levels of human IgM antibodies to Chikungunya virus using serum and plasma. This assay has a minimum analytical sensitivity limit to a diagn. >90%.
The minimum detection sensitivity level of human Chikungunya virus IgM using this human Chikungunya virus-IgM ELISA kit was to a diagn. >90%. The dynamic assay range for this kit is to a specific cut-off point.
- Evaluation of two IgM rapid immunochromatographic tests during circulation of Asian lineage Chikungunya virus. Southeast Asian J Trop Med Public Health. (2012) 43 (1): 55-61. Kosasih H., et al.
- Development and Evaluation of an in-House IgM-Capture ELISA for the Detection of Chikungunya and Its Application to a Dengue Outbreak Situation in Kenya in 2013. Jpn J Infect Dis. (2015) 68 (5): 410-4. Wasonga C., et al.
- Cloning, expression and evaluation of diagnostic potential of recombinant capsid protein based IgM ELISA for chikungunya virus. J Virol Methods. (2014) 203: 15-22. Priya R., et al.
- Correlation of plasma viral loads and presence of Chikungunya IgM antibodies with cytokine/chemokine levels during acute Chikungunya virus infection. J Med Virol. (2014) 86 (8): 1393-401. Reddy V., et al.
- [Dengue, Zika and Chikungunya]. Medicina (B Aires). (2016) 76 (2): 93-7. Spanish. Kantor I.N.
- A potent neutralizing IgMmAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis. MAbs. (2015) 7 (6): 1178-94. Lam S., et al.
- Full Name: Chikungunya Virus IgM µ-Capture ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Plasma
- Sensitivity: daign. >90%